With 1.2 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.5 million shares. During the session, the Drug Manufacturers – General company that operates in wider Healthcare sector, reached to the highest price of $142.3875 whereas the lowest price it dropped to was $140.05. The 52-week range on BIIB shows that it touched its highest point at $252.17 and its lowest point at $140.87 during that stretch. It currently has a 1-year price target of $226.42. Beta for the stock currently stands at -0.08.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIIB was down-trending over the past week, with a drop of -6.32%, but this was down by -5.87% over a month. Three-month performance dropped to -26.27% while six-month performance fell -38.15%. The stock lost -42.63% in the past year, while it has lost -7.64% so far this year. A look at the trailing 12-month EPS for BIIB yields 11.07 with Next year EPS estimates of 16.64. For the next quarter, that number is 3.41. This implies an EPS growth rate of 11.53% for this year and 1.33% for next year. EPS is expected to grow by 4.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -18.05%.
Float and Shares Shorts:
At present, 145.70 million BIIB shares are outstanding with a float of 144.68 million shares on hand for trading. On 2024-12-31, short shares totaled 3.68 million, which was 252.0 higher than short shares on 1732838400. In addition to Mr. Christopher A. Viehbacher as the firm’s President, CEO & Director, Mr. Michael R. McDonnell CPA serves as its Executive VP & CFO.
Institutional Ownership:
Through their ownership of 0.93171 of BIIB’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, BIIB reported revenue of $2465800000.0 and operating income of $496400000.0. The EBITDA in the recently reported quarter was $690000000.0 and diluted EPS was $2.66.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIIB since 32 analysts follow the stock currently. There are 27 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BIIB analysts setting a high price target of 342.0 and a low target of 138.0, the average target price over the next 12 months is 231.7069. Based on these targets, BIIB could surge 142.16% to reach the target high and fall by -2.29% to reach the target low. Reaching the average price target will result in a growth of 64.06% from current levels.
Analysts have provided yearly estimates in a range of $17.01011 being high and $16.13062 being low. For BIIB, this leads to a yearly average estimate of $16.42045. Based on analyst estimates, the high estimate for the next quarter is $4.45 and the low estimate is $3.43. The average estimate for the next quarter is thus $3.97.
